Lemborexant Treatment of Insomnia Linked to Epilepsy
RecruitingPhase 3
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Sleep-related focal epilepsy * Contraception Exclusion Criteria: * Changes in antiseizure medication 1 month before study protocol or during study protocol * Concomitant medications per SUNRISE1 * Individuals with hepatic impairment * Female participants who are pregnant or breastfeeding * Individuals with compromised respiratory function * Individuals with a history of complex sleep-related behaviour * Individuals with rare hereditary diseases of galactose intolerance such as galactosemia or glucose-galactose malabsorption * Individuals with a history of dependence or tolerance - abuse, dependence, rebound insomnia * Individuals with psychiatric disorders with abnormal thinking and behavioural changes, depression, or suicidal ideation * Individuals with a diagnosis of narcolepsy
About the study
The goal of this clinical trial is to assess whether Lemborexant can improve sleep in patients with epilepsy.
What is being tested
- Lemborexant (drug)
- Placebo (drug)
Sponsor: University of Manitoba · Participants: 26 · Started: Oct 29, 2024
Contact the study team
- Marcus C Ng, MD, FRCPC · Phone: 204-787-2684
Official record on ClinicalTrials.gov — NCT06262594
Locations in the U.S.
| North Carolina | Duke University, Durham (Not yet recruiting) |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.